Merck looks for next-generation opportunities in cardiometabolic drugs

Merck (MRK.N) is focused on second- and third-generation opportunities in the cardiometabolic drugs market, which includes weight-loss treatments, the U.S. drugmaker said on Tuesday.

"We think more in terms of small molecule orals, versus injectables. That's the preferred route," CEO Robert Davis said at the Goldman Sachs global healthcare conference.